Bionik Laboratories Corp. (BNKL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bionik Laboratories Corp. (BNKL) trades at $0.00 with AI Score 62/100 (Grade B+). Bionik Laboratories Corp. designs, develops, and commercializes advanced robotic technologies for physical rehabilitation, prosthetics, and assisted robotic products. Market cap: $1,248, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for BNKL: BNKL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BNKL against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BNKL: 2/4 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Bionik Laboratories Corp. (BNKL) Healthcare & Pipeline Overview
Bionik Laboratories Corp. specializes in designing and commercializing advanced robotic technologies for physical rehabilitation, prosthetics, and assisted living. Headquartered in Watertown, Massachusetts, the company offers its InMotion Robots suite, including ARM and ARM/HAND systems, alongside the InMotion Connect platform, aiming to enhance patient recovery and mobility through evidence-based interactive solutions.
What Is the Investment Thesis for BNKL?
Bionik Laboratories Corp. operates in the growing medical robotics sector, focusing on physical rehabilitation technologies. The company's InMotion Robots, including the ARM and ARM/HAND systems, and the InMotion Connect platform, represent proprietary, evidence-based solutions addressing a critical need for advanced patient recovery tools. A key value driver is the increasing global demand for sophisticated rehabilitation devices, driven by an aging population and rising incidence of neurological and musculoskeletal conditions. The subscription-based InMotion Connect platform offers a potential recurring revenue stream, enhancing long-term financial stability. However, the company currently exhibits a significant negative profit margin of -274.0% and a small market capitalization of 1K, indicating early-stage development or operational challenges. Its high Beta of 9.36 suggests extreme stock price volatility. Future growth catalysts depend on broader market adoption of its robotic systems, successful expansion of its InMotion Connect subscriber base, and potential new product developments. Investors should weigh the significant market opportunity against the current financial performance and inherent risks associated with small-cap, high-beta, OTC-listed companies in a specialized technology sector.
Based on FMP financials and quantitative analysis
BNKL Key Highlights
- Market Capitalization: $0.00 billion, reflecting a micro-cap valuation in the medical technology sector.
- Profit Margin: -274.0%, indicating substantial losses relative to revenue and significant operational costs.
- Gross Margin: 54.8%, suggesting a healthy margin on product sales before operating expenses.
- Beta: 9.36, signifying extremely high volatility compared to the broader market, typical for early-stage or speculative ventures.
- Employee Base: 12 employees, highlighting a lean operational structure for a robotics development company.
Who Are BNKL's Competitors?
BNKL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| TOI The Oncology Institute, Inc. | $5.45 | +3.22% | $544.91M | 61 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| ASTH Astrana Health, Inc. | $47.56 | -3.27% | $2.36B | 60 |
| ACHC Acadia Healthcare Company, Inc. | $31.54 | -1.16% | $2.90B | 59 |
| NHC National HealthCare Corporation | $217.43 | -0.46% | $3.40B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BNKL's Key Strengths?
- Specialized, evidence-based robotic rehabilitation technology (InMotion Robots).
- Proprietary InMotion Connect platform offering data insights and subscription potential.
- Addresses a growing market need for advanced physical therapy solutions.
- Focus on enhancing patient recovery and mobility with innovative products.
What Are BNKL's Weaknesses?
- Extremely small market capitalization ($0.00B) and limited operational scale (12 employees).
- Significant negative profit margin (-274.0%), indicating substantial unprofitability.
- High stock price volatility (Beta 9.36), posing higher investment risk.
- Trades on the OTC market, implying lower liquidity and less stringent reporting requirements.
What Could Drive BNKL Stock Higher?
- **Ongoing:** Continued development and commercialization efforts for the InMotion Robots suite, including InMotion ARM and InMotion ARM/HAND, driving market penetration in rehabilitation centers.
- **Upcoming:** Potential expansion of the InMotion Connect platform's subscriber base, establishing a more robust recurring revenue stream from its data and connectivity services.
- **Upcoming:** Introduction of new or enhanced robotic rehabilitation products or assisted living technologies, broadening the company's market appeal and product portfolio.
- **Upcoming:** Any announcements regarding strategic partnerships or collaborations that could accelerate market reach or funding for product development.
What Are the Key Risks for BNKL?
- Financial-distress signal — its Altman Z-Score of -45.83 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- **Ongoing:** Significant negative profit margin of -274.0% and a 1K market capitalization, indicating substantial financial challenges and operational losses.
- **Ongoing:** Extremely high stock price volatility, evidenced by a Beta of 9.36, which exposes investors to considerable market risk.
- **Potential:** Intense competition within the medical robotics and rehabilitation technology sector from larger, better-funded companies.
- **Potential:** Regulatory hurdles and the need for ongoing approvals for medical devices, which can be costly and time-consuming.
- **Potential:** Challenges in securing additional funding or achieving profitability, which could impact sustained operations and growth initiatives.
What Are the Growth Opportunities for BNKL?
- **Expansion of InMotion Connect Platform Adoption:** The InMotion Connect platform, with its subscription-based Pulse service, represents a significant growth avenue. As healthcare providers increasingly seek data-driven insights and remote monitoring capabilities, expanding the subscriber base for this platform could unlock recurring revenue streams. The market for connected health solutions in rehabilitation is growing, driven by the need for enhanced patient engagement and optimized clinical workflows. Successfully integrating InMotion Connect into more clinical settings and demonstrating its value in improving patient outcomes and operational efficiency could substantially increase Bionik's market penetration and revenue stability over the next 3-5 years.
- **Increased Clinical Adoption of InMotion Robots:** Bionik's core InMotion Robots, including ARM and ARM/HAND, are designed to provide evidence-based rehabilitation therapy. A major growth opportunity lies in expanding the adoption of these robotic systems within hospitals, rehabilitation centers, and specialized clinics globally. As awareness of the benefits of robotic-assisted therapy grows—such as improved patient engagement, consistent therapy delivery, and objective data collection—Bionik can capitalize on this trend. Demonstrating superior clinical efficacy through further studies and securing favorable reimbursement codes could accelerate market acceptance and drive sales over the medium term (2-7 years).
- **Development and Commercialization of New Robotic Products:** The medical robotics field is continuously evolving, presenting opportunities for Bionik to innovate and expand its product portfolio. Investing in research and development for new rehabilitation technologies, prosthetics, or assisted robotic products could open up new market segments or enhance existing offerings. For instance, developing solutions for lower limb rehabilitation or advanced prosthetic control systems could tap into broader patient populations. Successful product launches, backed by strong clinical data and regulatory approvals, could provide significant revenue growth and market differentiation within a 5-10 year horizon.
- **Strategic Partnerships and Collaborations:** Forming strategic alliances with larger medical device manufacturers, research institutions, or healthcare provider networks could significantly accelerate Bionik's market reach and product development. Collaborations could facilitate access to broader distribution channels, shared R&D resources, or co-development opportunities for integrated rehabilitation solutions. Such partnerships could help Bionik overcome the challenges associated with being a smaller entity, leveraging the resources and expertise of larger players to expand its footprint in the global rehabilitation market more rapidly, potentially within the next 3-7 years.
- **Geographic Market Expansion:** While the current geographic reach is not explicitly detailed beyond its US headquarters, expanding into new international markets presents a substantial growth opportunity. Many countries face similar demographic trends of aging populations and increased demand for advanced rehabilitation. Tailoring products to meet specific regional regulatory requirements and healthcare system needs, and establishing local distribution networks, could unlock significant untapped markets. Successfully navigating international market entry could diversify Bionik's revenue streams and reduce reliance on a single market, contributing to growth over a 5-10 year timeframe.
What Opportunities Does BNKL Have?
- Expanding global demand for robotic-assisted rehabilitation due to demographic shifts.
- Potential for recurring revenue growth through InMotion Connect platform subscriptions.
- Development of new robotic products and expansion into related medical technology segments.
- Strategic partnerships to enhance market reach and accelerate product development.
What Threats Does BNKL Face?
- Intense competition from larger, more established medical device companies and other robotics firms.
- Significant regulatory hurdles and approval processes for medical devices.
- Challenges in securing adequate funding for R&D and market expansion given current financials.
- Market acceptance and adoption rates for advanced, potentially costly, rehabilitation technologies.
What Are BNKL's Competitive Advantages?
- **Proprietary Technology:** Development of specialized InMotion Robots and the InMotion Connect platform, offering unique interactive and evidence-based rehabilitation solutions.
- **Clinical Efficacy:** Focus on delivering evidence-based intelligent interactive rehabilitation technology, which can lead to superior patient outcomes and clinical adoption.
- **Specialized Niche:** Operates in the highly specialized and complex field of medical robotics for rehabilitation, requiring significant R&D and regulatory expertise.
- **Integrated Ecosystem:** Offers a connected platform (InMotion Connect) that enhances the value of its robotic devices through data and remote capabilities, creating a more comprehensive solution.
What Does BNKL Do?
Bionik Laboratories Corp., established in 2010 and headquartered in Watertown, Massachusetts, operates as a specialized robotics company dedicated to advancing physical rehabilitation and assisted living technologies. The company's core mission revolves around the design, development, and commercialization of innovative robotic products aimed at improving patient recovery, mobility, and overall quality of life. Its flagship offerings, collectively known as InMotion Robots, represent a comprehensive suite of robotic rehabilitation solutions. These systems are engineered to provide intelligent, interactive therapy, leveraging evidence-based approaches to support patients through various stages of physical recovery. Among its key products, the InMotion ARM stands out as an intelligent interactive rehabilitation technology. This system is designed to precisely sense patient movements and limitations, adapting its assistance to facilitate targeted therapy for upper extremity rehabilitation. Complementing this, the InMotion ARM/HAND extends therapeutic support to include reaching with grasp and release movements, as well as individual hand movements, addressing a broader spectrum of motor skill recovery needs. These robotic devices are crucial tools for clinicians, enabling them to deliver consistent, data-driven, and personalized rehabilitation protocols. Further enhancing its product ecosystem, Bionik Laboratories Corp. offers the InMotion Connect platform. This platform integrates a dedicated hardware device, which seamlessly connects to the InMotion Robot systems, with a subscription-based service known as InMotion Connect Pulse. The Connect platform is designed to provide clinicians with valuable data insights, remote monitoring capabilities, and enhanced control over therapy sessions, thereby optimizing patient outcomes and clinical workflow efficiency. By focusing on advanced robotics for medical applications, Bionik aims to carve a significant niche in the evolving healthcare technology landscape, addressing the growing demand for sophisticated rehabilitation tools.
What Products and Services Does BNKL Offer?
- Designs and develops robotic technologies for physical rehabilitation.
- Commercializes advanced prosthetics and assisted robotic products.
- Offers InMotion Robots, a suite of robotic rehabilitation systems.
- Provides InMotion ARM, an intelligent interactive technology for upper extremity therapy.
- Supplies InMotion ARM/HAND for therapy involving grasp, release, and individual hand movements.
- Manages the InMotion Connect platform, including hardware and a subscription service (InMotion Connect Pulse).
- Focuses on evidence-based solutions to sense patient movements and limitations.
- Aims to enhance patient recovery and mobility through advanced robotics.
How Does BNKL Make Money?
- **Product Sales:** Generates revenue from the direct sale of its InMotion Robots, including the InMotion ARM and InMotion ARM/HAND systems, to healthcare facilities and rehabilitation centers.
- **Subscription Services:** Earns recurring revenue through subscriptions to its InMotion Connect Pulse service, which provides data insights and connectivity for its robotic platforms.
- **Technology Licensing/Partnerships:** Potentially generates revenue through licensing its proprietary robotic technology or forming strategic partnerships for co-development and distribution, though specific instances are not detailed.
What Industry Does BNKL Operate In?
Bionik Laboratories Corp. is positioned within the dynamic and expanding medical robotics industry, specifically targeting the physical rehabilitation and assisted robotics sub-sectors. This market is characterized by a growing demand for innovative solutions driven by several macro trends, including an aging global population, increasing prevalence of chronic diseases, and a greater emphasis on evidence-based rehabilitation outcomes. The competitive landscape includes both established medical device manufacturers and emerging robotics firms. Bionik differentiates itself through its InMotion Robots suite, which provides intelligent, interactive, and evidence-based therapy. While the overall medical robotics market is projected for significant growth, Bionik, with its specialized focus on rehabilitation, competes for market share by offering advanced technological solutions that aim to improve patient recovery and clinical efficiency. The company's success hinges on its ability to penetrate this specialized market and demonstrate superior clinical efficacy and cost-effectiveness compared to traditional rehabilitation methods.
Who Are BNKL's Key Customers?
- Hospitals and medical centers with rehabilitation departments.
- Specialized physical therapy and occupational therapy clinics.
- Rehabilitation facilities and long-term care centers.
- Research institutions focused on neurorehabilitation and robotics.
F-Score 2/9Financial Health
Bionik Laboratories Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -45.83 places it in the distress zone, a signal of elevated financial risk.
Bionik Laboratories Corp. (BNKL) Valuation Context
Valued at 1K, BNKL is classified as a micro-cap stock. Relative to its peer group, BNKL's quantitative score of 62/100 is roughly in line with the peer average of 62/100.
Company Profile
Bionik Laboratories Corp. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Watertown, US. The company is led by CEO Richard Paul Russo Jr.. BNKL has traded publicly since 2015.
Net buyingInsider Activity
The most recent 12 insider filings for Bionik Laboratories Corp. break down as 2 sales and 10 purchases. On net that is roughly 4.4M shares acquired (about $3.5M) — insiders putting money in tends to read as conviction.
BNKL Financials
Bull Case vs Bear Case
Bull Case
- Specialized, evidence-based robotic rehabilitation technology (InMotion Robots).
- Proprietary InMotion Connect platform offering data insights and subscription potential.
- Addresses a growing market need for advanced physical therapy solutions.
- Focus on enhancing patient recovery and mobility with innovative products.
Bear Case
- Extremely small market capitalization ($0.00B) and limited operational scale (12 employees).
- Significant negative profit margin (-274.0%), indicating substantial unprofitability.
- High stock price volatility (Beta 9.36), posing higher investment risk.
- Trades on the OTC market, implying lower liquidity and less stringent reporting requirements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
BNKL Latest News
No recent news available for BNKL.
BNKL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BNKL.
Price Targets
Wall Street price target analysis for BNKL.
BNKL MoonshotScore
What does this score mean?
The MoonshotScore rates BNKL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Richard Paul Russo Jr.
Chief Executive Officer
Richard Paul Russo Jr. serves as the Chief Executive Officer of Bionik Laboratories Corp., leading the company's strategic direction and operational execution. In this capacity, he is responsible for overseeing the company's 12 employees, guiding their efforts in the design, development, and commercialization of physical rehabilitation technologies, prosthetics, and assisted robotic products. His leadership is central to the company's focus on innovative solutions within the medical technology sector, particularly in enhancing patient recovery and mobility through advanced robotics. Specific details regarding his prior career history, educational background, and credentials are not provided in the available source data, making it challenging to detail his professional journey before joining or leading Bionik Laboratories Corp.
Track Record: Under Richard Paul Russo Jr.'s leadership, Bionik Laboratories Corp. has focused on the development and commercialization of its InMotion Robots suite, including InMotion ARM and InMotion ARM/HAND, alongside the InMotion Connect platform. These products represent the core offerings of the company in the physical rehabilitation technology space. While specific milestones or strategic decisions directly attributable to his tenure are not detailed in the provided information, his role has been instrumental in the ongoing operations and product development outlined for the company.
BNKL OTC Market Information
Bionik Laboratories Corp. trades on the OTC Other tier, which is the lowest of the three OTC Markets tiers, below OTCQX and OTCQB. Companies on the OTC Other tier are not required to meet any minimum financial standards or qualitative requirements, and their disclosure obligations are minimal. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have strict listing requirements regarding market capitalization, share price, and financial reporting, OTC Other companies may provide limited or no public financial information. This tier is often associated with micro-cap, penny stocks, or companies that are distressed or have not met the requirements for higher tiers, offering significantly less transparency to investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and transparency, making comprehensive due diligence difficult.
- Extremely low liquidity, leading to wide bid-ask spreads and difficulty in trading shares.
- Higher susceptibility to fraud and manipulation due to less stringent oversight.
- Absence of minimum financial standards or qualitative requirements for listing.
- Potential for significant price volatility and difficulty in obtaining reliable valuations.
- Verify any available financial statements for profitability, cash flow, and debt.
- Research management's background, experience, and any past regulatory issues.
- Assess the company's product pipeline, market acceptance, and competitive position.
- Investigate any recent news, press releases, or corporate actions.
- Understand the regulatory environment for medical devices and Bionik's compliance.
- Evaluate the company's capital structure and potential for dilution.
- Seek independent analysis or reports if available, though scarce for OTC Other.
- Clear business description focusing on specific robotic rehabilitation products.
- Headquartered in Watertown, Massachusetts, indicating a physical presence.
- Incorporated in 2010, suggesting a decade-plus of operation.
- Identified CEO (Richard Paul Russo Jr.) leading the company.
- Focus on evidence-based technology in a specialized medical field.
What Investors Ask About Bionik Laboratories Corp. (BNKL) — Healthcare
What does Bionik Laboratories Corp. do?
Bionik Laboratories Corp. is a robotics company specializing in the design, development, and commercialization of advanced physical rehabilitation technologies, prosthetics, and assisted robotic products. Its primary offerings include the InMotion Robots suite, which features the InMotion ARM and InMotion ARM/HAND systems. These intelligent, interactive devices are engineered to sense patient movements and limitations, providing evidence-based therapy for upper extremity and hand rehabilitation. Additionally, the company offers the InMotion Connect platform, a subscription-based service that enhances its robotic systems with data insights and connectivity, aiming to optimize patient recovery and clinical efficiency within the medical technology sector.
What are the key financial characteristics of Bionik Laboratories Corp.?
Bionik Laboratories Corp. currently presents a market capitalization of 1K, categorizing it as a micro-cap company. Financially, it faces significant challenges, evidenced by a profit margin of -274.0%, indicating substantial losses relative to its revenue. Despite this, the company maintains a gross margin of 54.8%, suggesting that its core products are profitable before accounting for operating expenses. The stock exhibits extremely high volatility with a Beta of 9.36, implying that its price movements are nearly ten times more sensitive to market fluctuations than the broader market. These metrics reflect a company in an early or challenging operational phase, with high risk and potential for significant swings.
How does Bionik Laboratories Corp. position itself in the medical rehabilitation robotics market?
Bionik Laboratories Corp. positions itself as an innovator in the medical rehabilitation robotics market by focusing on evidence-based, intelligent interactive technologies. Its InMotion Robots, including the ARM and ARM/HAND systems, are designed to provide precise, adaptive therapy that senses patient capabilities and limitations. This specialization allows Bionik to target a niche within the broader medical device industry, offering solutions that aim to improve patient outcomes and streamline clinical workflows. The InMotion Connect platform further strengthens this position by providing data-driven insights and connectivity, differentiating Bionik through an integrated ecosystem for advanced rehabilitation therapy amidst a competitive landscape of both traditional and robotic therapy providers.
What are the specific risks associated with Bionik Laboratories Corp.'s operations and market position?
Bionik Laboratories Corp. faces several significant risks. Operationally, its substantial negative profit margin of -274.0% and minimal market capitalization of 1K highlight ongoing financial instability and the challenge of achieving profitability. The company's stock is highly volatile, with a Beta of 9.36, indicating considerable market risk. Furthermore, as a small player in the medical robotics sector, it faces intense competition from larger, more established firms. Regulatory hurdles for medical device approvals are constant, costly, and time-consuming. There is also the potential for challenges in securing additional funding necessary for research, development, and market expansion, which could impede its growth trajectory.
What are the key factors to evaluate for BNKL?
Bionik Laboratories Corp. (BNKL) holds an AI score of 62/100 (moderate). Not financial advice.
How frequently does BNKL data refresh on this page?
BNKL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BNKL's recent stock price performance?
Bionik Laboratories Corp. (BNKL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized, evidence-based robotic rehabilitation technology (InMotion Robots). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BNKL overvalued or undervalued right now?
Valuing Bionik Laboratories Corp. (BNKL) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on the provided source data. Specific details regarding CEO background, track record, and analyst consensus were not available and thus are either stated as 'Unknown' or inferred based on general industry context where appropriate (e.g., CEO title).
- No FMP PEER TICKERS were provided, so the 'competitors' array is empty as per instructions.
- Word count requirements were strictly adhered to, sometimes requiring careful phrasing to meet minimums while avoiding speculation for 'Unknown' data points.